Mronja Yönelik Teşhis ve Tedavi Yaklaşımları

Boston B, Ipe D, Capitanescu B, Gresita A, Hamlet S, Love R, et al. Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients. Journal of the American Geriatrics Society. 2023;71(8):2640-52.

Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2003;61(9):1115-7.

Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2010;68(5):959-63.

Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. The British journal of oral & maxillofacial surgery. 2010;48(3):221-3.

Kün-Darbois JD, Fauvel F. Medication-related osteonecrosis and osteoradionecrosis of the jaws: Update and current management. Morphologie : bulletin de l'Association des anatomistes. 2021;105(349):170-87.

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2014;72(10):1938-56.

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2022;80(5):920-43.

Body JJ, Mancini I. Bisphosphonates for cancer patients: why, how, and when? Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2002;10(5):399-407.

Kanis JA, Gertz BJ, Singer F, Ortolani S. Rationale for the use of alendronate in osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 1995;5(1):1-13.

Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2005;63(11):1567-75.

Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. The oncologist. 2004;9 Suppl 4:28-37.

Martins AS, Correia JA, Salvado F, Caldas C, Santos N, Capelo A, et al. Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws - A retrospective cohort study. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery. 2017;45(10):1736-42.

Otto S, Troeltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development? Journal of Cranio-Maxillofacial Surgery. 2015;43.

Shintani T, Hayashido Y, Mukasa H, Akagi E, Hoshino M, Ishida Y, et al. Comparison of the prognosis of bisphosphonate-related osteonecrosis of the jaw caused by oral and intravenous bisphosphonates. International journal of oral and maxillofacial surgery. 2015;44(7):840-4.

Eguia A, Bagán-Debón L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw. Medicina oral, patologia oral y cirugia bucal. 2020;25(1):e71-e83.

Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature clinical practice Oncology. 2006;3(1):24-40.

AlRowis R, Aldawood A, AlOtaibi M, Alnasser E, AlSaif I, Aljaber A, et al. Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies. The Saudi dental journal. 2022;34(3):202-10.

Sakkas A, Heil S, Kargus S, Rebel M, Mischkowski RA, Thiele OC. Tocilizumab: Another medication related to osteonecrosis of the jaws? A case report and literature review. GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW. 2021;10:Doc03.

Otto S, Aljohani S, Fliefel R, Ecke S, Ristow O, Burian E, et al. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ). Medicina (Kaunas, Lithuania). 2021;57(5).

Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. International journal of implant dentistry. 2021;7(1):47.

Sırlı Yılmaztürk S, Bozdemir E. İlaç Kullanımına Bağlı Çene Kemiklerinin Osteonekrozunun Ortaya Çıkmasında Rol Oynayan Risk Faktörleri Ve Klinik, Radyografik Özellikleri. Dental and Medical Journal - Review. 2020;2(3):95-110.

Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, et al. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. The Journal of clinical endocrinology and metabolism. 2022;107(5):1441-60.

Migliorati CA. Oral Complications in Cancer Patients-Medication-Related Osteonecrosis of the Jaw (MRONJ). Frontiers in oral health. 2022;3:866871.

Yazıcı T, Şentürk MF, Koçer G. Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi. 2017;8(2):50-7.

Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral surgery, oral medicine, oral pathology and oral radiology. 2019;127(2):117-35.

Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2015;30(1):3-23.

Eşer G, Duman ŞB, Başaran M, Aşantoğrol F. Manyetik Rezonans Görüntüleme ve Diş Hekimliği. Black Sea Journal of Health Science. 2022;5(1):130-7.

Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dento maxillo facial radiology. 2006;35(4):236-43.

Ottesen C, Schiodt M, Jensen SS, Kofod T, Gotfredsen K. Tooth extractions in patients with cancer receiving high-dose antiresorptive medication: a randomized clinical feasibility trial of drug holiday versus drug continuation. Oral surgery, oral medicine, oral pathology and oral radiology. 2022;133(2):165-73.

Fortunato L, Bennardo F, Buffone C, Giudice A. Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review. Journal of Cranio-Maxillofacial Surgery. 2020;48(3):268-85.

Ragazzo M, Val M, Montagner G, Trojan D, Fusetti S, Guarda Nardini L. Human amniotic membrane: an improvement in the treatment of Medication-related osteonecrosis of the jaw (MRONJ)? A case–control study. Cell and Tissue Banking. 2022;23(1):129-41.

Sivri D, Atak S, ÇEtİNer S, Öztürk K, Okur B. Medication Related Osteonecrosis of the Jaws: Definition, Prevention, Treatment and Current Approaches. Turkiye Klinikleri Journal of Dental Sciences. 2020;26:462-71.

Govaerts D, Piccart F, Ockerman A, Coropciuc R, Politis C, Jacobs R. Adjuvant therapies for MRONJ: A systematic review. Bone. 2020;141:115676.

de Castro MS, Ribeiro NV, Jr., de Carli ML, Pereira AA, Sperandio FF, Hanemann JA. Photodynamically dealing with bisphosphonate-related osteonecrosis of the jaw: Successful case reports. Photodiagnosis and photodynamic therapy. 2016;16:72-5.

Tartaroti NC, Marques MM, Naclério-Homem MDG, Migliorati CA, Zindel Deboni MC. Antimicrobial photodynamic and photobiomodulation adjuvant therapies for prevention and treatment of medication-related osteonecrosis of the jaws: Case series and long-term follow-up. Photodiagnosis and photodynamic therapy. 2020;29:101651.

Hidaka K, Mikuni-Takagaki Y, Wada-Takahashi S, Saita M, Kawamata R, Sato T, et al. Low-intensity pulsed ultrasound prevents development of bisphosphonate-related osteonecrosis of the jaw-like pathophysiology in a rat model. Ultrasound in Medicine & Biology. 2019;45(7):1721-32.

Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon R, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. Journal of oral and Maxillofacial Surgery. 2007;65(7):1321-7.

Agrillo A, Ungari C, Filiaci F, Priore P, Iannetti G. Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. The Journal of craniofacial surgery. 2007;18(5):1071-5.

Morishita K, Yamada S-i, Kawakita A, Hashidume M, Tachibana A, Takeuchi N, et al. Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): A multicenter retrospective analysis in Japan. Journal of Orthopaedic Science. 2020;25(6):1079-83.

Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2010;110(5):593-6.

Pazouki MR, Golestaneh A, Aminzadeh A. Effectiveness of local application of simvastatin for prevention of bisphosphonate-related osteonecrosis of the jaw: An animal study on rats. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. 2022;34(6):713-8.